| Entry |
|
|---|
| Name |
Tyrosine kinase inhibitor to MET exon 14 skipping
|
|---|
| Definition |
(Capmatinib,Tepotinib) -| MET* |
|---|
| Expanded |
(D10891,D11073) -| 4233v4 |
|---|
| Type |
Drug target
|
|---|
| Gene |
| 4233 | MET; MET proto-oncogene, receptor tyrosine kinase |
|
|---|
| Variant |
|
|---|
| Perturbant |
| D10891 | Capmatinib hydrochloride |
| D11073 | Tepotinib hydrochloride |
|
|---|
| Reference |
|
|---|
| Authors |
Van Der Steen N, Giovannetti E, Pauwels P, Peters GJ, Hong DS, Cappuzzo F, Hirsch FR, Rolfo C |
|---|
| Title |
cMET Exon 14 Skipping: From the Structure to the Clinic. |
|---|
| Journal |
|
|---|
| Reference |
|
|---|
| Authors |
Drilon A, Cappuzzo F, Ou SI, Camidge DR |
|---|
| Title |
Targeting MET in Lung Cancer: Will Expectations Finally Be MET? |
|---|
| Journal |
|
|---|
| LinkDB |
|
|---|
